0
0
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s Imaavy, a groundbreaking treatment for myasthenia gravis (gMG), a rare autoimmune disorder that weakens skeletal muscles and impairs critical functions like breathing, speaking, and movement. The drug, acquired through J&J’s $6.5 billion purchase of Momenta Pharmaceuticals in 2020, is poised to generate over $5 billion in peak sales and could reach $23 billion by 2032, according to Leerink analysts.
Targeting Autoantibodies
Imaavy is approved for patients aged 12 and older and specifically neutralizes two autoantibodies responsible for disrupting nerve-muscle communication. David Lee, head of J&J’s global immunology division, emphasized its precision: “There are various types of antibodies capable of disrupting the interaction between the muscle and the nerve. Imaavy addresses two key drivers of the disease.” The therapy covers over 90% of gMG patients, a condition affecting approximately 100,000 people in the U.S.
Competitive Landscape and Pricing
The drug will compete with existing therapies from Argenx SE, AstraZeneca, and UCB. J&J has set a list price of $12,480 per 1,200-milligram vial, though patient costs will vary based on insurance. The approval follows a 24-week late-stage trial showing significant improvements in patients’ ability to perform daily activities.
Future Expansion
J&J is exploring Imaavy’s potential for other immune disorders, including Sjögren’s syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), which could further broaden its market reach.
Disclaimer: This article is based on information from a Reuters report (https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-jjs-immune-disorder-drug-2025-04-30/) and includes forward-looking statements. Actual sales, pricing, and therapeutic outcomes may differ due to market, regulatory, or clinical factors. Consult healthcare professionals for medical advice.
Stay updated on healthcare innovations with the Reuters Health Rounds newsletter.
Citations:
